|
[Nivolumab for the treatment of advanced melanoma] |
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nivolumab for the treatment of advanced melanoma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 543. 2017 Authors' conclusions High quality evidence showed that the use of nivolumab as first-line therapy, in patients with advanced (metastatic or irresecable) melanoma without BRAF mutations would increase the rate of one year progression-free and overall survival when compared with dacarbazine. In this setting, its use in combination with ipilimumab would increase progression-free survival and the incidence of severe adverse effects, although the results on overall survival are not available yet. In patients who progressed after ipilimumab or BRAF inhibitors, its use as monotherapy would increase progression-free survival with a lower incidence of adverse effects when compared with the use of chemotherapy. No comparative studies versus other options currently considered first or second-line therapy (pembrolizumab or BRAF/MEK inhibitors) have been found.
There is consensus among the clinical practice guidelines to recommend its use as an option in first line and/or second line therapy; being covered in these situations by different public and private health sponsors consulted. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000308 Date abstract record published 13/06/2017 |
|
|
|